Analysis of Patients With Autosomal Dominant Polycystic Kidney Disease Focusing on Clinical and Genetic Data and Effects of Tolvaptan or Octreotide Therapy

What this Trial Is About

Researchers are establishing a detailed database of clinical and genetic information for patients diagnosed with Autosomal Dominant Polycystic Kidney Disease (ADPKD). This study focuses especially on patients who have received specific treatments, such as Tolvaptan or Octreotide, at a specialized renal genetics outpatient clinic. The research includes analyzing clinical, laboratory, and imaging outcomes to understand the disease's progression and treatment effects. Participants will undergo thorough personal and family history collection, with data recorded and updated during regular outpatient visits. The study monitors kidney function decline using measures such as creatinine, eGFR, proteinuria, and urinary osmolarity. Imaging scans track changes in kidney cyst number and size over time, comparing patients receiving treatment with those who are not. Secondary goals include monitoring cardiovascular issues, urinary tract complications, liver involvement, and side effects related to the specific therapies. During the study, participants will have ongoing evaluations including clinical assessments, laboratory tests, and imaging studies. Researchers will track disease progression toward end-stage renal failure and assess treatment impact on various health parameters. The study's data collection and monitoring will continue for five years to build a comprehensive understanding of ADPKD and its management.

Analysis of Patients With Autosomal Dominant Polycystic Kidney